Abstract

Background

The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

Results

This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included.

Conclusion

Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Details

Title
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Author
Bernardes Emerson 1 ; Caravan, Peter 2 ; Michael, van Dam R 3 ; Deuther-Conrad Winnie 4   VIAFID ORCID Logo  ; Ellis, Beverley 5 ; Furumoto Shozo 6 ; Guillet, Benjamin 7 ; Ya-Yao, Huang 8 ; Jia Hongmei 9 ; Laverman, Peter 10 ; Li Zijing 11 ; Liu Zhaofei 12 ; Lodi Filippo 13 ; Miao Yubin 14 ; Perk Lars 15 ; Schirrmacher Ralf 10 ; Vercoullie Johnny 16 ; Yang, Hua 17 ; Yang, Min 18 ; Yang, Xing 19 ; Zhang, Junbo 9 ; Ming-Rong, Zhang 20 ; Zhu, Hua 21 

1  IPEN, São Paulo, Brazil (GRID:grid.466806.a) (ISNI:0000 0001 2104 465X) 
2  Harvard University, Massuchusetts General Hospital, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
3  University of California, Los Angeles, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718) 
4  Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Leipzig, Germany (GRID:grid.40602.30) (ISNI:0000 0001 2158 0612); Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany (GRID:grid.40602.30) (ISNI:0000 0001 2158 0612) 
5  Manchester University NHS Foundation Trust, Manchester, UK (GRID:grid.498924.a) (ISNI:0000 0004 0430 9101) 
6  Tohoku University, CYRIC, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
7  CERIMED, C2VN, Aix-Marseille Univ, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817) 
8  National Taiwan University College of Medicine, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241) 
9  Beijing Normal University, Beijing, China (GRID:grid.20513.35) (ISNI:0000 0004 1789 9964) 
10  University of Alberta, Edmonton, Canada (GRID:grid.17089.37) (ISNI:0000 0001 2190 316X) 
11  Xiamen University, Xiamen, China (GRID:grid.12955.3a) (ISNI:0000 0001 2264 7233) 
12  Peking University, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
13  S. Orsola-Malpighi Hospital, Bologna, Italy (GRID:grid.412311.4) 
14  University of Colorado, Denver, USA (GRID:grid.241116.1) (ISNI:0000000107903411) 
15  Radboud University Medical Center, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382) 
16  University of Tours, Tours, France (GRID:grid.12366.30) (ISNI:0000 0001 2182 6141) 
17  TRIUMF, Vancouver, Canada (GRID:grid.232474.4) (ISNI:0000 0001 0705 9791) 
18  Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, People’s Republic of China (GRID:grid.412676.0) (ISNI:0000 0004 1799 0784) 
19  Peking University First Hospital, Beijing, China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621) 
20  NIRS, Chiba, Japan (GRID:grid.482503.8) (ISNI:0000 0004 5900 003X) 
21  Peking University Cancer Hospital, Beijing, China (GRID:grid.412474.0) (ISNI:0000 0001 0027 0586) 
Publication year
2022
Publication date
Dec 2022
Publisher
Springer Nature B.V.
e-ISSN
2365-421X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s41181-022-00162-3
ProQuest document ID
2655331266
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.